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Background
Deficient or absent secretion of parathyroid hormone (PTH) is the
biochemical hallmark of hypoparathyroidism, a clinical disorder
which may occur in combination with other endocrine (or non-en-
docrine) defects or as a solitary endocrinopathy termed isolated
hypoparathyroidism. Molecular genetic studies indicate that iso-
lated hypoparathyroidism may be caused by mutations in a vari-
ety of genes, including genetic defects that impair synthesis (i.e.,
PTH gene defects) (1) or secretion (i.e., CASR gene defects) (2)
of PTH as well as defects that impair the embryological develop-
ment of the parathyroid glands (i.e. GCMB) (3). However, genetic
hypoparathyroidism most commonly occurs in the context of
complex development disorders that are associated with parathy-
roid dysembryogenesis. The HDR syndrome is an autosomal
dominant disorder that in its complete form is manifested by hy-
poparathyroidism deafness, and renal abnormalities in associa-
tion with haploinsufficiency of the G A TA 3 gene located at 10p15
(4, 5). The pathogenesis of the developmental anomalies caused
by G A T A 3 mutations is not well understood, and the spectrum of
clinical phenotypes has not been fully characterized. Given the
small number of cases that have been described, molecular ge-
netic studies offer the opportunity to develop a more comprehen-
sive understanding of phenotypic variability among affect sub-
jects. In this paper we report the clinical features of three affected
members of an extended family with HDR.
Case report
The index patient is a 27-year-old female of Azhkanazi Jewish
ancestry with a past medical history of multiple childhood uri-
nary tract infections that required urethral dilatation. At age 23,
she underwent a partial right nephrectomy for an infected renal
cyst. One week prior to admission to our hospital, she noted
the onset of right flank pain, fever, and chills. A computed to-
mography scan of the abdomen showed multiple cysts in the
right kidney, one of which appeared infected, and the patient
was admitted for treatment with antibiotics and percutaneous
drainage. Review of systems was significant for nonprogres-
sive sensorineural deafness diagnosed at the age of five years,
and mild idiopathic hirsutism that was responsive to oral con-
traceptives. The patient had no history of seizures or tetany.
Physical examination disclosed normal blood pressure, a high-
arched palate and thin, unfolded auricular helices. Chvostek’s
and Trousseau’s signs were absent. Costovertebral angle ten-
derness was present on the right side. The remainder of the
physical examination was normal.
Laboratory studies (Table I) revealed a serum total calcium lev-
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Table I - Relevant laboratory values and medical history for the proband and her mother.
Proband Mother
Ionized calcium, mmol/L (normal range 1.10-1.45) 1.01 –
Serum calcium, mg/dL (9.0-10.5) 6.4 7.6
Serum phosphate, mg/dL (3.0-4.5) 6.2 3.9
Albumin, mg/dL (3.5-5.0) 3.8 4.3
Creatinine, mg/dL (0.7-1.2) 0.7 0.9
Serum-intact parathyroid hormone, pg/ml (10-65) 8 15
25-(OH) vitamin D, pg/ml (9-52) 28 –
24 hour urine calcium, mg (0-250) 186 –
Sensorineural hearing loss Yes Yes
Structural renal abnormalities Yes Unknown
Karyotype Normal Normal
GATA 3 sequencing Missense mutation exon 5, Missense mutation exon 5, 
Asn320Lys Asn320Lys
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el of 6.4 mg/dL (normal 9.0-10.5 mg/dL), albumin 3.8 g/dL (3.5-
5.0 g/dL), phosphate 6.2 mg/dL (3.0-4.5 mg/dL), and magne-
sium 2.1 mg/dL (1.3-2.0 mg/dL). Serum ionized calcium was
1.01 mmol/L (1.10-1.45 mmol/L), and intact-PTH was 8 pg/mL
(10-65). The levels of 25(OH) vitamin D (28 ng/mL) and
1,25(OH) vitamin D (28 pg/mL) were both normal. A twenty-
four hour urine collection showed a calcium excretion of 186
mg (0-250). Hepatic and renal function tests were normal. The
patient was treated with IV piperacillin/tazobactam, and her in-
fected renal cyst was drained percutaneously. She denied
symptoms of hypocalcemia and was discharged after one
week on antibiotics. Months later, a section of the patientÕs
right kidney was removed surgically and histology revealed
cysts, a markedly dilated calyceal system, focal tubular atro-
phy, interstitial fibrosis, glomerular sclerosis, lymphocytic infil-
trate, and interstitial calcifications.
Family studies
The patient’s mother had longstanding sensorineural hearing
loss and hypoparathyroidism. The concentration of serum cal-
cium was 7.6 mg/dL with an albumin level of 4.3 g/dL. Serum
intact PTH was 15 pg/mL. Renal function was normal. Imaging
of her kidneys was not available. The father had normal renal
function and normal serum concentrations of calcium and intact
PTH. There was no history of hearing or genitourinary abnor-
malities.
The patient’s brother had a history of nonprogressive sen-
sorineural deafness, but information regarding potential renal
or parathyroid abnormalities was not available. A sister has re-
current hemolytic-uremic syndrome, but no known parathyroid
or hearing abnormalities. There was no history of hearing dys-
function, renal abnormalities, or hypoparathyroidism in any of
the patient’s grandparents or other extended family.
Genetic studies
Informed consent for genetic testing was obtained from the pa-
tient and both of her parents. This study was approved by the
Joint Committee on Clinical Investigation of the Johns Hopkins
University School of Medicine. High resolution karyotyping was
normal in the patient (46, XX), her mother (46, XX), and her fa-
ther (46,XY). Leukocyte genomic DNA was isolated by usual
methods from the three subjects. Exons and flanking intronic
sequences of the calcium-sensing receptor gene (CASR/
PCAR1, OMIM 601199), P T H gene (OMIM 168450), and the
G A T A 3 gene (OMIM 131320) were amplified by the poly-
merase chain reaction and sequenced directly. Sequences of
the P T H and C A S R genes were normal, but a heterozygous
missense mutation (AAfi AAC, Asn320Lys) in exon 5 of the
GATA3 gene was identified in both the index patient and her
mother and was confirmed to impair GATA3 function (6).
Discussion
In this report we describe a patient with the complete HDR syn-
drome, including renal dysplasia, nonprogressive sensorineural
deafness, and hypoparathyroidism, in association with a novel
missense mutation in the GATA3 gene. Genetic analysis con-
firmed the same mutation in the patient’s mother, who mani-
fested only hypoparathyroidism and deafness. This report em-
phasizes the phenotypic variability of the HDR syndrome, and
suggests that future molecular genetic studies may document
other GATA3 mutations in some patients who have only one or
wo of the three features of this syndrome. 
Early clinical reports had described an association between hy-
poparathyroidism, renal disease, and deafness prior to the dis-
covery of GATA3 mutations in patients with the HDR syndrome
(4). Barakat et al described two young male siblings and male
twins with a steroid-resistant nephrotic syndrome that pro-
gressed to renal failure and death at an early age (7). This was
accompanied by sensorineural deafness and hypoparathy-
roidism. One grandmother and three of her siblings had early
onset deafness, but none had renal failure, and the interval
generation had normal hearing, calcium levels and renal func-
tion. Dahlberg et al described two brothers with congenital dif-
fuse lymphedema, hypoparathyroidism, small, inadequately
functioning kidneys, but normal audiogram (8). The brothers al-
so had mitral valve prolapse, bilateral cataracts, brachydactyly
and other morphologic abnormalities. No renal failure, hypocal-
cemia, or deafness was found in any other family member. Yu-
mita et al described three affected patients in two different fam-
ilies with hypoparathyroidism and progressive hearing loss (9).
All but one had bilateral cataracts, and one of the three (unre-
lated to the other two) had hypoplasia of one kidney. No com-
ment was made on renal abnormalities in the others. Baldellou
et al described a young boy with primary hypoparathyroidism
and unilateral renal agenesis, with a normal karyotype, no fam-
ily history, and several dysmorphic features, such as low set
ears, beaked nose, talipes equinovarus, in addition to mental
retardation. No hearing deficit was noted (10). Shaw et al re-
ported four cases from three Asian families of hypoparathy-
roidism, developmental delay, and renal insufficiency (11). All
had a severe distal renal tubular acidosis requiring bicarbonate
supplementation, with oxalate crystals seen in the collecting
system of two of them. Two of these patients, who were unre-
lated, also had evidence of nerve deafness. Watanabe et al de-
scribed a family with five family members affected by autoso-
mal hypoparathyroidism and deafness, but all had normal kid-
neys. Sequencing of the PTH1 gene and CASR were normal
(12).
The clinical triad that constitutes the complete HDR syndrome
was first described in 1992 by Bilious et al in four patients who
had hypoparathyroidism, nonprogressive sensorineural deaf-
ness, and renal dysplasia (13). The original report also de-
scribed additional relatives with partial or incomplete character-
istics, including two patients who had renal dysplasia alone,
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Figure 1 - Family pedigree showing affected family members. II-3 is the
proband, known to be fully affected. I-2 has hypoparathyroidism and
nonprogressive sensorineural deafness. II-5 also has sensorineural
deafness, showing an autosomal dominant mode of transmission. II-1
has recurrent Hemolytic-Uremic Syndrome. II-2 and II-4 were first
trimester miscarriages.
I-1 I-2
Hypoparathyroidism
SensoineuralDeafness
II-1 II-2 II-3 II-4 II-5
Hypoparathyroidism Sensoineural Deafness
Sensoineural Deafness
Renal Dysplasia
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and two others with low serum calcium levels who died in in-
fancy. In 1997, Hasegawa et al. described a young Japanese
girl with a hypoparathyroidism, deafness, and agenesis of the
right kidney (14). She also had a ventricular septal defect, psy-
chomotor retardation, and micrognathia. A terminal deletion
was found from 10pter-10p13 by karyotyping. Other family
members were not affected. 
In 2000, Van Esch et al discovered mutations in G A T A 3 a n d
concluded that haplo-insufficiency of GATA3 is responsible for
the HDR syndrome (4). Deletion of this region (10p15) can lead
to a variant of DiGeorge’s syndrome (DGS2), which includes
HDR in addition to cardiac, mental, and facial defects, addition-
al features that our patient did not have (15). The young Japan-
ese girl described by Hasegawa had a larger deletion in this
area (detectable by karyotyping), likely explaining the other
physical findings noted (14).
Muroya, et al reported heterozygous mutations in seven of nine
Japanese families with the HDR phenotype. These GATA3 mu-
tations included a missense mutation within the first zinc finger
domain in exon 4, an insertional mutation also in exon 4
(900insAA plus 901insCCT or C901AACCCT) resulting in a
premature stop codon with loss of the second zinc finger do-
main, and a nonsense mutation at exon 6. Four other families
had heterozygous deletion of G AT A 3 by fluorescence in situ
hybridization (FISH) analysis (5).
The G A T A 3 gene consists of 6 exons that span 17kb of ge-
nomic DNA, and belongs to a family of zinc-finger transcription
factors that are involved in vertebrate embryonic development.
Homozygous G A T A 3 knockout mice display high embryonic
lethality and multiple abnormalities of the central nervous sys-
tem and the immune system along with features of the human
HDR syndrome, but lack parathyroid defects (16). The patho-
genesis of the developmental anomalies caused by G A T A 3
mutations is not well understood. Therefore, given the small
number of cases identified, phenotype-genotype correlations
may lead to better understanding of the role of GATA3 in the
embryological development of the ear, kidney, and parathyroid
gland.
There is great phenotypic variability in the families and individ-
uals affected by the HDR syndrome (Table II). The expressivity
of the three principal components is variable, and renal dys-
morphism appears to be lowest at 67%, while hypoparathy-
roidism is highest at 89%. Age of onset of each is notable for
early diagnosis of deafness, which is largely nonprogressive.
Hypoparathyroisism and renal dysmorphism have been diag-
nosed in infancy in symptomatic patients (5, 13), but have also
been diagnosed in elderly asymptomatic relatives of affected
patients (4, 12). In all cases, the manifestations of HDR syn-
drome are believed to be early onset or congenital, though un-
detected well into adulthood, and no adult death has yet been
attributed directly to progression of the HDR syndrome. Other
manifestations, such as cardiac or facial defects, occur more
commonly in patients who have large deletions that include the
GATA3 gene (5). The lack of immune deficiency in patients af-
fected by HDR is surprising, as GATA3 is heavily involved in T-
cell development and function, especially with regard to IL-5
expression (17). Yet, none of the reported cases, nor the family
that we present here had documented immune deficiency. The
only infections of note in our index patient have been related to
structural abnormalities in the urologic organs. Her mother and
brother have had no similar course of repeated infections. The
variable expression and penetrance in the HDR syndrome is
consistent with other pleiotropic developmental disorders.
Genes involved in human development frequently show a wide
range of penetrance depending on other genetic and environ-
mental factors.
Parathyroid agenesis/dysgenesis is also a component the Di-
George syndrome (DGS1), which most commonly results from
deletion at 22q11.2 (15). A common denominator appears to
be a defect in the embryological development of neural crest
cells. The 22q11.2 deletion syndrome (del22q11DS) is consid-
ered the most common microdeletion syndrome in humans, oc-
curring in approximately 1 out of 5000 live births. Most cases of
DGS1 are sporadic, but familial occurrence with apparent auto-
somal dominant inheritance has been described (18, 19). In
these cases a heterozygous deletion of chromosomal region
22q11.2 is inherited from a mildly affected parent (20, 21). The
associated embryological defects that characterize the pheno-
type caused by loss of genes in the 22q11 region have been
compiled to create the acronym “CATCH22”, which refers to
Cardiac anomalies, Abnormal facies, Thymic aplasia, Cleft
palate, and Hypocalcemia with deletion at 22q. Because hy-
poparathyroidism in patients with DiGeorge syndrome can be
transient, with resolution during infancy, all infants with congen-
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Table II - Summary of HDR phenotypes from current and prior reports.
Report Number Number with Number with Number with Other Mean age (yrs.) 
affected hypoparathyroidism deafness renal abnormalities at diagnosis
(%) (%) abnormalities (range)
(%) 
McWilliams, et al., 2004 3 2/2 (100%) 3/3 (100%) 1/3 (33%) Hirsutism 39 (27-51)
Bilious, et al., 1992 8 6/8* (75%) 4/8 (50%) 6/8 (75%) 12 (neonatal-38)
Hasegawa, et al., 1997 1 1/1 (100%) 1/1 (100%) 1/1 (100%) VSD, psychomotor 2 (2)
retardation, 
micrognathia, 
del 10pter-10p13
Watanabe, et al., 1998 5 5/5 (100%) 3/5 (60%) 0/5 (0%) 16 (28 days-35 
years)
Muroya, et al., 2001 16 11/13 (85%) 9/11 (82%) 13/16 (81%) VSD, pyloric  28 (1-70)
stenosis, CVA
Van Esch, et al., 2000 9 9/9 (100%) 9/9 (100%) 7/9 (78%) NR
Total 42 34/38 (89%) 29/37 (78%) 28/42 (67%) 33 (neonatal-70)
*Two died in infancy with low serum calcium, hypoparathyroidism is presumed, VSD=Ventricular Septal Defect, CVA=Cerebrovascular Accident, NR=not re-
p o r t e d .
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ital hypoparathyroidism should be thoroughly evaluated for the
genetic and physical defects associated with CATCH-22 syn-
drome. The clinical findings in patients with del22q11 can be
highly variable, and some authors have used the term “com-
plete DGS” to describe the disorder in an infant with thymic
aplasia, parathyroid aplasia, and one of the usual conotruncal
cardiac defects. These infants may present with neonatal
tetany, cardiac failure, recurrent infections and failure to thrive.
The term “partial DGS” then refers to the disorder with less se-
vere and often delayed manifestations. The minimal diagnostic
criteria for the partial form are difficult to define. Analysis of the
human DGS1 deleted region on chromosome 22q11.2 has de-
fined a 250-kb minimal critical region that includes a variety of
candidate genes, and haploinsufficiency of Tbx1 has emerged
as the likely explanation for the developmental defects of
DGS1, as some patients with del22q11 phenotype but without
chromosomal deletion have Tbx1 gene mutations (22).
Hypoparathyroidism occurs as a component of other complex
developmental syndromes. The Kenny-Caffey syndrome and
Sanjad-Sakati syndrome are both caused by mutations in tubu-
lin-specific chaperone E (TBCE) on 1q43 (23, 24). Renal and
auditory abnormalities are not present in affected subjects.
Thus, the combination of hypoparathyroidism, impaired audio-
logical activity, and renal dysmorphism provides strong clinical
evidence of HDR syndrome.
Conclusions
We report a case of HDR syndrome, a rare, inherited cause of
deafness, hypoparathyroidism, and renal dysmorphism. G A T A 3
haplo-insufficiency has been reported in very few families with
a characteristic HDR phenotype. Affected individuals have a
50% likelihood of transmitting the mutation to offspring. With
the exception of those who have died from hypocalcemia in in-
fancy, life expectancy of those affected does not appear to be
altered, though long-term studies are lacking. Because the ab-
normalities can be largely asymptomatic as in the case we pre-
sent, and because the phenotypic expression of the syndrome
seems to be highly variable, clinicians should have a high in-
dex of suspicion when early onset or congenital hypoparathy-
roidism is identified. A thorough family history and a careful ex-
amination of hearing and renal structures are recommended.
Elucidation of the role of GATA3 in embryonic development will
be required to understand the basis for the HDR phenotype.
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